Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Allen Seiden

Otolaryngic Allergy Cincinnati, OH Medical Doctor

NPI 1255375051 CMS profile 284133

222 Piedmont Ave, Cincinnati, OH 45219

Open in the dashboard

General payments

$14,192

31 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Allen Seiden of Cincinnati, OH is reported in the CMS Open Payments database as having received $14,192 across 31 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $2,309 6
2021 General $3,868 4
2020 General $2,286 5
2019 General $5,729 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Allen Seiden
  • Otolaryngic Allergy median
  • Middle half of Otolaryngic Allergy
  • National median

In program year 2025, general payments to Allen Seiden were reported at $0. Among 69 Otolaryngic Allergy profiles paid that year, the median was $420 and the middle half received between $149 and $981.

Show as a table
Year Allen Seiden Otolaryngic Allergy median Middle half National median
2019 $5,729 $206 $52–$646 $163
2020 $2,286 $158 $40–$529 $114
2021 $3,868 $225 $68–$696 $132
2022 $2,309 $364 $108–$1,004 $149
2023 $0 $272 $123–$1,038 $160
2024 $0 $416 $129–$1,844 $164
2025 $0 $420 $149–$981 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. OptiNose US, Inc. $13,399 21 payments
  2. Aerin Medical Inc. $432 4 payments
  3. GlaxoSmithKline, LLC. $171 2 payments
  4. Stryker Corporation $152 2 payments
  5. Acclarent, Inc $38 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,950 8 payments
  2. Honoraria $2,500 1 payment
  3. Consulting Fee $2,000 1 payment
  4. Food and Beverage $1,203 18 payments
  5. Travel and Lodging $539 3 payments
Products named General payments · program years 2019–2022
  1. Xhance $13,399 21 payments
  2. Vivaer RF Stylus $432 4 payments
  3. NUCALA $171 2 payments
  4. ENTELLUS - XPRESS ENT DILATION SYSTEM $152 2 payments
  5. ACCLARENT AERA EUSTACHIAN TUBE BALLOON DILATION SYSTEM $20 1 payment
  6. Relieva Ultirra $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

84

Median for Otolaryngology: 297

Drug cost

$2,716

Median for Otolaryngology: $6,314

Branded share of claims

0%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Budesonide Generic 14 $1,769
Azelastine Hcl Generic 16 $402
Montelukast Sodium Generic 12 $214
Fluticasone Propionate Generic 20 $178
Famotidine Generic 22 $153

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Records

31 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngic Allergy in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record